US SEC Trading Suspension Halt Orders — April 02, 2026

02-04-2026

CytoSorbents Corporation received a 180-day extension from Nasdaq until September 28, 2026, to regain compliance with the Minimum Bid Price Requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2), following its initial 180-day period that ended March 31, 2026, without compliance. The extension has no immediate effect on the listing of its Common Stock (CTSO) on Nasdaq Capital Market and does not impact SEC reporting obligations. While the Company intends to monitor the bid price and consider options like a reverse stock split, there is no assurance of regaining compliance, posing a continued delisting risk.

• ·Previous non-compliance notification received October 2, 2025, for 30 consecutive business days of sub-$1.00 closing bid price.
• ·Compliance can be regained if Common Stock bid price closes at $1.00 or higher for minimum 10 consecutive trading days prior to September 28, 2026.
• ·Nasdaq Listing Rule 5810(c)(3)(A) governs the extension.

02-04-2026

On March 27, 2026, Datasea Inc. received a Nasdaq staff determination notice indicating its common stock (DTSS) failed to comply with the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2) for 30 consecutive business days prior to the notice. The company has an initial 180 calendar days until September 23, 2026, to regain compliance by maintaining a $1.00 closing bid price for 10 consecutive business days, with no immediate delisting effect and potential for a second 180-day extension if other listing standards are met. Datasea intends to monitor the stock price and consider options such as a reverse stock split to cure the deficiency.

• ·Nasdaq Listing Rule 5550(a)(2) violated due to 30 consecutive business days below $1.00 bid price
• ·Potential eligibility for second 180-day compliance period requires meeting market value of publicly held shares and other initial listing standards (except bid price)
• ·Company principal executive offices: Room 302-5, Building C, Gemdale Viseen International Center, No. 5 Shengfang Road, Daxing District, Beijing, China 102600

02-04-2026

Vistagen Therapeutics, Inc. notified Nasdaq of non-compliance with Listing Rule 5605(c)(2), which requires an Audit Committee of at least three independent members, following Mary Rotunno's resignation from the Board effective April 1, 2026, reducing the committee to two members. The company's common stock listing on Nasdaq Capital Market remains unaffected, with a cure period extending to the earlier of the next annual stockholders' meeting or one year from the resignation date (or 180 days if the meeting occurs within that timeframe). The Board intends to regain compliance before the cure period expires.

• ·Non-compliance disclosed in prior 8-K filed March 18, 2026.
• ·Nasdaq Listing Rule 5605(c)(2) specifically requires three independent Audit Committee members.
• ·Cure period pursuant to Nasdaq Listing Rule 5605(c)(4)(B).

02-04-2026

On April 2, 2026, the NYSE notified Solo Brands, Inc. that it will commence delisting proceedings for its Class A common stock due to failure to maintain an average global market capitalization of at least $15 million over 30 trading days under Rule 802.01B, with trading suspended after market close. The stock is expected to begin trading on the OTCQB Venture Market on April 6, 2026, under symbol 'SBDS', though liquidity and market-making are not guaranteed. CEO John Larson emphasized that operations, strategic priorities, and financial position remain unchanged, with a sound balance sheet, debt covenant compliance, and ongoing focus on cash flow generation and profitability improvements.

• ·Company has right to appeal delisting to NYSE Board of Directors Committee and is evaluating the option.
• ·If no appeal or unsuccessful, NYSE will file Form 25 with SEC; delisting effective 10 days after filing.
• ·Registrant is an emerging growth company.
• ·Class A Common Stock has $0.001 par value per share.

02-04-2026

Fusemachines Inc. received a Nasdaq deficiency notice on March 27, 2026, stating that its securities failed to maintain the minimum Market Value of Listed Securities (MVLS) of $50,000,000 for 30 consecutive business days, per Listing Rule 5450(b)(2)(A). There is no immediate impact on listing, with common stock (FUSE) and warrants (FUSEW) continuing to trade, and the company has 180 calendar days until September 23, 2026, to regain compliance by achieving the MVLS threshold for 10 consecutive business days. The company plans to monitor its MVLS and explore options to comply, though success is not guaranteed amid market and operational risks.

• ·Nasdaq compliance determination based on last 30 consecutive business days prior to March 27, 2026
• ·Company classified as emerging growth company